Overview
| 别名 | Histone-lysine N-methyltransferase SETD2; HIF-1; Huntingtin yeast partner B; Huntingtin-interacting protein 1; HIP-1; Huntingtin-interacting protein B; Lysine N-methyltransferase 3A; Protein-lysine N-methyltransferase SETD2; SET domain-containing protein 2; hSET2; p231HBP |
| 基因名 | SETD2 |
| UniProt ID | Q9BYW2 |
| 反应种属 | Human |
| 应用 | IHC-P |
| 宿主 | Mouse |
| 偶联物 | Unconjugated |
| 修饰 | Unmodified |
| 亚型 | IgG1 |
| 克隆号 | 6D8-M7-P2 |
| 克隆性 | Monoclonal Antibody |
| 分子量 | Calculated MW: 287 kDa |
| 纯化方式 | Affinity Purified |
| 产品形式 | Liquid |
| 推荐稀释比 | IHC-1:200 |
| 存储缓冲液 | Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.09% sodium azide |
| 保存温度 | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| 背景信息 | SET domain containing 2, histone lysine methyltransferase (SETD2) is the primary enzyme responsible for the trimethylation of histone H3 at lysine 36 (H3K36me3). This epigenetic mark is essential for transcriptional elongation, alternative splicing, and DNA damage repair via homologous recombination. SETD2 interacts with RNA polymerase II through its WW and SRI domains and also methylates non-histone substrates, including α-tubulin, actin, and STAT1, thereby influencing cytoskeleton dynamics and antiviral immunity. Clinically, SETD2 functions as a potent tumor suppressor, and its inactivation is a hallmark of several malignancies. It is most notably mutated in clear cell renal cell carcinoma (ccRCC), where the loss of H3K36me3 leads to genomic instability, p53 destabilization, and enhanced metastasis. Its role in suppressing cryptic transcription and maintaining chromosomal integrity is fundamental to preventing oncogenic transformation. |
检测原理